Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine

Journal of Medical Virology

Volumn 60, Issue 1, 2000, Pages 77-85

  McClain, David J ^a,b   Summers, Peter L ^a   Harrison, Stephen A ^a   Schmaljohn, Alan L ^a   Schmaljohn, Connie S ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b 445 Biltmore Center   (United States)

Author keywords

Hantaan virus; Hantavirus; Vaccinia vectored vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS VACCINE; VIRUS VECTOR;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HANTAVIRUS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INOCULATION; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCAR FORMATION; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINIA VIRUS; VIRUS HEMORRHAGIC FEVER; VIRUS RECOMBINANT;

ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HANTAAN VIRUS; HUMANS; IMMUNIZATION, SECONDARY; LYMPHOCYTE ACTIVATION; NEUTRALIZATION TESTS; VACCINATION; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL VACCINES;

EID: 0033991941     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(200001)60:1<77::AID-JMV13>3.0.CO;2-S     Document Type: Article

References (9)

1. Asada H, Balachandra K, Tamura M, Kondo K, Yamanishi K. 1989. Cross-reactive immunity among different serotypes of virus causing haemorrhagic fever with renal syndrome. J Gen Virol 70:819-825.
2. Chakrabarti S, Brechling K, Moss B. 1985. Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Bio 5:3403-3409.
3. Chu Y-K, Jennings GB, Schmaljohn CS. 1995. A vaccinia-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses, but not Puumala virus. J Virol 69: 6417-6423.
4. McClain DJ, Harrison S, Yeager CL, Cruz J, Ennis FA, Gibbs P, Wright MS, Summers PL, Arthur JD, Graham JA. 1997. Immunologic responses to vaccinia vaccines administered by different parenteral routes. J Infect Dis 175:756-763.
5. Schmaljohn A, Li D, Negley D, Bressler D, Turell M, Korch G, Ascher M, Schmaljohn C. 1995. Isolation and initial characterization of a new hantavirus from California. Virology 206:963-972.
6. Schmaljohn C, Dalrymple J, McClain D, Malinoski F, LeDuc J. 1994. Preclinical trials of recombinant vaccines for Hantaan virus, cause of hemorrhagic fever with renal syndrome. In: Talwar G, Rao K, Chauha V, editors. Recombinant and synthetic vaccines. New Delhi, India: Narosa Publishing House. p 332-339.
7. Schmaljohn C, Hasty S, Dalrymple J. 1992. Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome. Vaccine 10:10-13.
8. Schmaljohn C, Hjelle B. 1997. Hantaviruses: a global disease problem. Emerg Infect Dis 3:95-104.
9. Schmaljohn CS, Chu YK, Schmaljohn AL, Dalrymple JM. 1990. Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J Virol 64:3162-3170.